Therapy-related acute promyelocytic leukemia

Haematologica

Volumn 96, Issue 4, 2011, Pages 493-495

  Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; GEMTUZUMAB OZOGAMICIN; GYRASE INHIBITOR; IDARUBICIN; MITOXANTRONE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL (TOPIC); DISEASE PREDISPOSITION; DNA DAMAGE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GENETIC SUSCEPTIBILITY; HIGH RISK POPULATION; HUMAN; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; PHARMACOGENETICS; PROMYELOCYTIC LEUKEMIA; SIDE EFFECT; SOLID TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASMS, SECOND PRIMARY; OXIDES; RADIOTHERAPY, COMPUTER-ASSISTED;

EID: 79953885688     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.041970     Document Type: Editorial

References (20)

1. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood. 1994;83(10):2780-2786.
2. Pulsoni A, Pagano L, Lo Coco F, Avvisati G, Mele L, Di Bona E, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood. 2002;100(6):1972-1976.
3. Beaumont M, Sanz M, Carli PM, Maloisel F, Thomas X, Detourmignies L, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003;21(11):2123-2137.
4. Hasan SK, Mays AN, Ottone T, Ledda A, La Nasa G, Cattaneo C, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood. 2008;112(8):3383-3390.
5. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, et al. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer. 2011;117(1):110-115.
6. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med. 2005;352(15):1529-1538.
7. Mays AN, Osheroff N, Xiao Y, Wiemels JL, Felix CA, Byl JA, et al. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocyt-ic leukemia. Blood. 2010;115(2):326-330.
8. Ammatuna E, Montesinos P, Hasan SK, Ramadan SM, Esteve J, Hubmann M, et al. Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica 2011;96(4):621-625.
9. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010;28(24):3866-3871.
10. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006;17(1):131-134.
11. Hu J, Liu YF, Wu C F, Xu F, Shen ZX, Zhu YM, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2009;106(9):3342-3347.
12. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27(4):504-510.
13. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751-3757.
14. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA. 2004;101(15):5328-5335.
15. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469-3473.
16. Garcia-Manero G, Kantarjian HM, Kornblau S, Estey E. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia. 2002;16(9):1888.
17. Montesinos P, Gonzalez JD, Gonzalez J, Rayon C, de Lisa E, Amigo ML, et al. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. J Clin Oncol. 2010;28(24):3872-3879.
18. Imagawa J, Harada Y, Shimomura T, Tanaka H, Okikawa Y, Hyodo H, et al. Clinical and genetic features of therapy-related myeloid neoplasms after chemotherapy for acute promyelocytic leukemia. Blood. 2010;116(26):6018-6022.
19. Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MA, Breccia M, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood. 2002;99(3):822-824.
20. Pedersen-Bjergaard J. Insights into leukemogenesis from therapy-related leukemia. N Engl J Med. 2005;352(15):1591-1594.